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ABSTRACT
In the present study we evaluated the feasibility of unrelated cord blood transplantation (UCBT) in patients with
severe aplastic anemia (SAA). The outcome of 31 SAA patients (median age 28; range: 0.9-72.3 years old) who
received UCBT was analyzed. The cumulative incidences of the neutrophil and platelet recovery after UCBT
were 54.8 and 72.2%, respectively (95% confidence interval [CI] 5 36.0%-70.3% and 51.3%-85.3%, respec-
tively). The cumulative incidences of grade$II acute and chronic graft-versus-host disease (aGVHD, cGVHD)
were 17.1% (95% CI 5 6.2%-32.8%) and 19.7% (95% CI 5 6.2%-38.8%), respectively. Currently, 13 patients
are alive, having survived for 33.7 months (median; range: 6-77 months) after UCBT. The probability of overall
survival (OS) at 2 years was 41.1% (95% CI 5 23.8%-57.7%). A conditioning regimen that included low-dose
total body irradiation (TBI) (2-5 Gy), fludarabine, and cyclophosphamide resulted in a favorable OS (80%;
95% CI 5 20.4%-96.9%). This result suggests that UCBT using the optimal conditioning regimen can be
a salvage treatment for patients without a suitable bone marrow donor and warrants evaluation in further
prospective studies.
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Over the last 2 decades, the outcome of patients
with severe aplastic anemia (SAA) has dramatically
improved regardless of whether patients received im-
munosuppressive therapy (IST) or bone marrow trans-
plantation (BMT) [1-3]. BMT from an HLA-matched
sibling is curative in the majority of younger patients
with SAA, and is currently recommended as first-line
treatment [4]. IST, with a combination of antithymo-
cyte globulin (ATG) and cyclosporine (CSA), has
been an alternative therapy for patients without an
HLA-matched sibling. BMT from an unrelated donor
(UD) is used as a salvage therapy for patients who failto respond to IST or who experience a relapse of the
disease. However, in general, the results of UD-
BMT have been inferior to those achieved with an
HLA-matched sibling.
The report the Center for International Blood and
Marrow Transplant Research (CIBMTR) on UD-
BMT (n 5 231), for the period 1988-1998, showed
that the overall survival (OS) rates for matched and
mismatched UD-BMT in patients with SAA were
39% and 36%, respectively [5]. The Japan Marrow
Donor Program (JMDP) reported a favorable outcome
with 56% survival rate in 154 patients with SAA who
received UD-BMT between 1993 and 2000 [6]. In1057
1058 A. Yoshimi et al.the recent 2 reports from the European Group for
Blood and Marrow Transplantation (EBMT) and the
French Society of Bone Marrow Transplantation and
Cellular Therapy (SFGM-TC), the outcomes of
UD-BMT for SAA before and after 1998 were com-
pared. The results demonstrated improved OS rates
of UD-BMT since year 1998 (32% versus 57% for
EBMT and 29% versus 50% for SFGM-TC) [7,8].
The authors speculated that the better HLA matching
because of the introduction of high-resolution HLA
typing may have contributed to the improved out-
comes. In pediatric series, 90% OS rates have been
recently reported for UD-BMT patients, which is
comparable to that observed for BMT from a matched
sibling [9,10].
Treatment approaches for patients who lack a suit-
able unrelated bone marrow donor remain a great
challenge. Cord blood has been used as an alternative
source of HSCT, and it has the advantages of rapid
availability on demand and a low incidence of graft-
versus-host disease (GVHD). There were only a few
reports on unrelated cord blood transplantation
(UCBT), which included patients with SAA. The re-
sults showed poor outcome and high incidence of graft
failure [11,12]. However, a few small series and case re-
ports of successful UCBT for SAA have recently been
reported [13-17]. Because of the possible reporting
bias, the general efficacy of UCBT is still unknown.
Therefore, we decided to further examine this proce-
dure by using the database of the Japan Cord Blood
Bank Network (JCBBN). We identified 31 patients




From September 1998 until February 2006, 53 pa-
tients with acquired SAA received UCBT through
JCBBN. Twenty-two patients who received UCBT
as a salvage therapy for the engraftment failure after
previous HSCT were excluded, and the remaining 31
patients were included in this study. Patient character-
istics and the cord blood units are summarized in
Table 1. Patients were eligible for UCBT if they had
no HLA-identical related or unrelated bone marrow
donor. Patients who could not wait for UD-BMT
because of unstable diseases were also considered to
be eligible for UCBT. Cord blood units with 0 to 2
HLA locus mismatches by serology in HLA-A,
HLA-B, and HLA-DRB1 were searched and then
the unit with the largest cell dose was selected. At least
2.0 107/kg mononuclear cells (MNCs) were given in
all patients.
The age of the patients ranged 0.9 to 72.7 years
(median 27.9 years), and there were 8 patients older
than 50 years of age. There were 25 patients whohad been previously treated with IST, including
ATG 1 CSA (n 5 13), ATG only (n 5 4), or CSA
only (n 5 8). In 4 patients, androgen had been given.
The remaining 2 patients were given only supportive
therapy. All patients or their guardians gave informed
consent for transplantation and submission of the data
to the JCBBN.
Recipient-Donor HLA Matching
Data were available for 31 patients with serology-
based recipient-donor HLA matching and for 22 pa-
tients who underwent high-resolution DNA typing
for class I-HLA-A, HLA-B, and DRB1 (Table 1).
The HLA disparities for both GVHD and rejection
directions are shown in Table 1.
Transplantation Procedure
Characteristics of the transplantation procedures
are listed in Table 2. The conditioning regimens var-
ied according to the individual centers used. The 3
most commonly used regimens were: TBI (4-5 Gy)
1 fludarabine (FLU; 120-175 mg/m2) 1 Melphalan
(MEL) (80-120/mg/m2) (n 5 12), TBI (2-4 Gy) 1
FLU (90-250/mg/m2) and cyclophosphamide (CY;
50-100 mg/kg or 2250/mg/m2) (n 5 5), and TBI
(10-12 Gy) 1 CY (120-200 mg/kg) 1 ATG (n 5 3).
Of the 25 patients given irradiation, 24 received TBI
Table 1. Patient and Donor Characteristics (n 5 31)
Characteristic




Etiology of aplastic anemia
Idiopathic/hepatitis associated (n) 30/1
Disease duration before UCBT: median,
days (range)
337 (31-5063)
1 year or less/ 1-3 year/3 year or
more/unknown (n)
13/4/8/5
Red blood cell transfusions before UCBT
Less than 20 times/20 or more
times/unknown (n)
8/21/2
Platelet transfusions before UCBT
Less than 20 times/20 or more
times/unknown (n)
7/22/2
HLA mismatches (serologic): GVHD
direction (n 5 31)
0/1/2 (n) 4/18/9
HLA mismatches (serologic): rejection
direction (n 5 31)
0/1/2 (n) 6/17/8
HLA mismatches (DNA typing): GVHD
direction (n 5 22)
0/1/2/3/4 (n) 2/6/6/6/2
HLA mismatches (DNA typing): rejection
direction (n 5 22)
0/1/2/3/4 (n) 1/5/12/3/1
UCBT indicates unrelated cord blood transplantation; GVHD,
graft-versus-host disease.
Unrelated UCBT for Severe Aplastic Anemia 1059and 1 underwent thoracoabdominal irradiation. A total
of 7 patients were administered with ATG, either
horse ATG (Lymphoglobulin 30-75 mg/kg in 5 pa-
tients) or rabbit ATG (Thymoglobulin 10 mg/kg in
2 patients). GVHD prophylaxis also varied according
to the individual centers (Table 2). To facilitate the re-
covery of neutrophils, all patients received recombi-
nant human granulocyte colony-stimulating factor.
The number of mononucleated cells, colony-forming
units of granulocyte-macrophage (CFU-GM), and
CD34-positive cells of the cord blood units at the
time of freezing are shown in Table 2.
Definitions and Statistical Analysis
The status of all patients was evaluated based on
the last follow-up report, which was performed using
the standardized forms provided by the JCBBN. All re-
sults were analyzed as of June 2008.
Date of engraftment was defined as the first of the 3
consecutive days where the neutrophil recovery was
.0.5 109/L. Platelet recovery was defined as the first
of the 3 consecutive days where the unsupported plate-
let count was .50  109/L. Chimerism was evaluated
in 12 patients, with fluorescent in situ hybridization for
the Y chromosome performed in 6 sex-mismatched
grafts and quantitative polymerase chain reaction anal-
Table 2. Transplant Procedures (n 5 31)
No. of Patients
Conditioning Regimen
TBI (4-5 Gy) 1 MEL1 FLU 12
TBI (2-4 Gy) 1 CY 1 FLU 5









CSA 1 others (MTX/steroid/MMF) 10
Tacrolimus 7
Tacrolimus 1 others (MTX/steroid) 8
MNC cell dose
$2.0  107/kg,\ 3.0  107/kg 15
$ 3.0  107/kg 16
CFU-GM cell dose
\ 2.0  104/kg 14
$ 2.0  104/kg 15
Unknown 2
CD34 cell dose
\ 1.0  105/kg 10
$ 1.0  105/kg 15
Unknown 6
TBI indicates total body irradiation; TAI, thoracoabdominal irradia-
tion;MEL,melphalan;FLU,fludarabine;CY, cyclophosphamide;
ATG, antithymocyte globulin; CSA, cyclosporine; MTX, metho-
terxate; MMF, mycophenolate mofetil; MNC, mononuclear cell;
CFU-GM, colony-forming unit granulocyte-macrophage.ysis for microsatellite DNA markers performed in 6
sex-matched transplantations. Acute and chronic
GVHD (aGVHD, cGVHD) were diagnosed and
graded according to standard clinical criteria [18,19].
Probability of OS was estimated according to the
Kaplan-Meier method. GVHD and engraftment
were assessed using the cumulative incidence proce-
dure, and death was the competing event. Univariate
comparisons among various groups were made using
the log-rank test. The variables evaluated included
age of the patient, donor sex, sex mismatch, disease du-
ration before UCBT, the number of pre-UCBT trans-
fusions for red cells and platelets, IST before UCBT,
HLA matching by serology and high-resolution
DNA typing for both GVHD and rejection directions,
the number of mononuclear cells, CFU-GM, CD34-
positive cells of the cord blood units at the time of
freezing, conditioning regimens, and the administra-
tion of ATG and GVHD prophylaxis (single agent
versus $2 agents, MTX versus no MTX, or CSA ver-
sus tacrolimus). All statistical analyses were carried out




Sustained engraftment was observed in 17 patients.
The cumulative incidences of the neutrophil and plate-
let recovery after UCBTwere 54.8 and 72.2%, respec-
tively (95% confidence interval [CI] 5 36.0%-70.3%
and 51.3%-85.3%, respectively; Figure 1). The me-
dian times to achieve a neutrophil count $0.5  109/l
and a platelet count $50  109/l were 19 days (range:
12-35 days) and 59 days (range: 39-145 days), respec-
tively. Chimerism analysis results were available in 8
patients with sustained neutrophil engraftment. All
of these patients showed complete donor chimerism
with more than 99% donor cells. No mixed chimerism
was observed. There were 7 patients who failed to
achieve sustained engraftment among patients who
survived more than 28 days after UCBT. Five patients
did not achieve a primary engraftment. Although 3 of
them underwent a second UCBT, all died of infec-
tions, with (n 5 1) or without (n 5 2) engraftment of
the second graft. Autologous recovery was noted in 1
patient, which was proven by the chimerism analysis
that demonstrated 100% recipient cells. One patient
had achieved engraftment on day 19, but she suffered
from late graft failure at day 176 and received second
HSCT at day 203. The patient was still alive at the
time of the last follow-up.
Results of the univariate analysis for engraftment
are shown in Table 3. The GVHD prophylaxis with
a single agent (CSA or tacrolimus) exhibited a signifi-
cantly better engraftment rate than that seen for the
other methods (75.0% versus 33.3%, P 5 0.02).
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Figure 1. (A) Cumulative incidence of sustained donor neutrophil engraftment (.0.5 109/L) and (B) platelet engraftment (.50 109/L) after
unrelated cord blood transplantation in patients with aplastic anemia.When there was a lower number of transfusions (\20
times) of red cells and platelets prior to the HSCT,
there was a trend for a better chance of successful en-
graftment compared to cases where there were highernumber of transfusions ($20 times), although this was
not statistically significant. The number of infused
MNCs, CFU-GM, and CD34 had no impact on the
engraftment.Table 3. Outcome following Unrelated Cord Blood Transplantations for Aplastic Anemia: Univariate Analysis
Covariates 2-Year-OS (%) (95% CI) P Engraftment (%) (95% CI) P
Recipient age
\20 year (n 5 9) 44.4 (13.6-71.9) .18 44.4 (13.6-71.9) .76
20- 40 year (n 5 12) 56.3 (24.4-79.1) 66.7 (33.7-86.0)
.40 year (n 5 10) 20.0 (3.0-47.5) 50.0 (18.4-75.3)
Disease duration before UCBT
\1 year (n 5 13) 35.7 (13.0-59.4) .34 57.1 (28.4-78.0) .67
$1 year (n 5 12) 47.6 (18.2-72.4) 58.3 (27.0-80.1)
RBC transfusions before UCBT
\20 (n 5 8) 62.5 (22.9-86.1) .26 75.0 (31.5-93.1) .08
$20 (n 5 21) 31.4 (13.1-51.7) 47.6 (25.7-66.7)
Platelet transfusions before UCBT
\20 (n 5 7) 57.1 (17.2-83.7) .28 85.7 (33.4-97.9) .05
$20 (n 5 22) 35.0 (16.1-54.7) 45.4 (24.4-64.3)
HLA matching by serologic typing (GVHD direction)
0-1 mismatched (n 5 22) 49.2 (27.3-68.0) .34 63.6 (40.3-79.9) .10
2 mismatched (n 5 9) 22.2 (3.4-51.3) 33.3 (78.3-62.3)
HLA matching by serologic typing (Rejection direction)
0-1 mismatched (n 5 23) 43.5 (23.3-62.1) .64 52.2 (30.5-70.0) .59
2 mismatched (n 5 8) 37.5 (8.7-67.4) 62.5 (22.9-86.1)
Conditioning regimen
TBI 1 CY 1 FLU (n 5 5) 80.0 (20.4-96.9) .02 75.0 (40.8-91.2) .17
TBI 1 MEL 1 FLU (n 5 12) 46.9 (17.6-71.9) 80.0 (20.4-96.9)
Others (n 5 14) 21.4 (5.2-44.8) 28.6 (08.8-52.4)
ATG
No (n 5 24) 48.9 (27.8-67.0) .007 66.7 (44.3-81.7) .19
Yes (n 5 7) 14.3 (0.7-46.5) 14.3 (0.7-46.5)
GVHD prophylaxis
CSA or tacrolimus only (n 5 13) 54.6 (27.4-75.3) .07 75.0 (46.3-89.8) .02
CSA or tacrolimus1others (n 5 18) 26.7 (8.3-49.6) 33.3 (12.2-56.4)
MTX
No (n 5 20) 38.5 (17.7-59.1) .93 60.0 (35.7-77.6) .24
Yes (n 5 11) 45.5 (16.7-70.7) 45.5 (16.7-70.7)
MNC
2  107/kg-3  107/kg (n 5 15) 45.0 (19.4-67.8) .61 60.0 (31.8-79.7) .70
$3  107/kg (n 5 15) 37.5 (15.4-59.8) 50.0 (24.-71.0)
CD34
\1  105/kg (n 5 15) 45.7 (14.3-73.0) .32 70.0 (32.9-89.2) .52
$1  105/kg (n 5 15) 33.3 (12.2-56.4) 53.3 (26.3-74.4)
GVHD indicates graft-versus-host disease; TBI, total-body irradiation; CY, cyclophosphamide; Mel, melpharan; Flu, fludarabine; ATG, antith-
ymocyte globulin; CSA, cyclosporine; MTX, methotrexate; MNC, mononuclear cell; CFU-GM, colony-forming unit-granulocyte macro-
phage; UCBT, unrelated cord blood transplantation.
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Acute GVHD ($grade II) was observed in 5 pa-
tients (grade II; n 5 4, grade III; n 5 1) on days 8
through 56, and was lethal in the 1 patient with grade
III aGVHD. Chronic GVHD was observed in 4 pa-
tients (extensive: n 5 1, limited: n 5 3; de novo n 5 2,
progression from aGVHD n5 2) on days 124 through
213. Figure 2 depicts the cumulative incidence of grade
II-IV aGVHD (17.1%; 95% CI 5 6.2%-32.8%) and
cGVHD (19.7%; 95% CI5 6.2%-38.8%). Viral reac-
tivations were commonly observed in this study. CMV
reactivationwasnoted in9patients, and1of themdevel-
oped CMV disease. Epstein-Barr virus (EBV) reactiva-
tion was noted in 1 patient, having developed cerebral
infarction, which was considered to be related with
EBV. Adenovirus induced cystitis occurred in 1 patient.
Survival
Of the 31 total patients, 13 are presently alive, with
survival durations of 6 to 77 months (median 33.7
months) after the transplantations. The probability
of OS at 2 years was 41.1% (95% CI 5 23.8%-
57.7%). The results of univariate analysis of the factors
influencing survival are shown in Table 3. The condi-
tioning regimen and the administration of ATG were
the only factors that were significantly related to the
survival. The conditioning regimen, which included
low-dose TBI, FLU, and CY, resulted in better out-
comes than were seen for the other regimens (Table 3
and Figure 3). The administration of ATG was associ-
ated with poor outcome (Table 3 and Figure 3). There
were 5 out of 7 patients given ATG that died before
engraftment because of infections (n 5 3) or hepatic
veno-occlusive disease (VOD) (n 5 2). In the 2 other
patients, 1 demonstrated autologous recovery, whereas
the other patient has had sustained engraftment and is
currently still alive. There tended to be a better out-
come noted for GVHD prophylaxis with a single agent
(either CSA or tacrolimus) compared to prophylaxis
with 2 or more agents. The outcome for the patients
aged 40 years and older was inferior to that seen for
the younger patients, although this was not statistically
significant.In the 18 patients who died, the causes of death
were graft failure (n 5 7), bacterial/fungal infections
(n 5 3), EBV-related cerebral infarction (n 5 1),
VOD (n 5 3), aGVHD (n 5 1), acute respiratory dis-
tress syndrome (n 5 1), encephalopathy (n 5 1), and
cardiac toxicity (n 5 1).
DISCUSSION
The outcome of 31 patients with SAA who re-
ceived UCBT was analyzed in this study. This is the
first report on a nationwide multicentral study that fo-
cused onUCBT for SAA as far as we know.The overall
survival rate was 41%, which is comparative to the re-
sults of the large registry-based analysis of UD-BMT
for SAA by CIBMTR [5], but inferior to the results
of some recent reports of UD-BMT [6,20]. The inci-
dence and the severity of aGVHD and cGVHD were
considerably lower in this study, which is advantageous
for UCBT. The major problem encountered, how-
ever, was still the high incidence of engraftment failure
after UCBT. In the present study the conditioning
regimen with the low-dose TBI, FLU, and CY re-
sulted in better outcome (80% survival rate) compared
to other regimens. This regimen and the selection of
optimal donor with better HLA match and higher
cell dose may improve the outcome of UCBT for SAA.
Previous reports on the conditioning regimen of
UCBT for SAA are limited. Mao et al. [13] reported
on 9 patients with SAA who were conditioned with
ATG and CY (60 mg/kg) prior to undergoing
UCBT. A total of 7 out of 9 of these patients survived
with hematologic recovery. However, a donor-recipi-
ent mixed chimerism was present in all patients. There
are a few case reports of UCBT for SAA usingmore in-
tensified regiments, which resulted in successful en-
graftment along with complete chimerism [14-16,21].
Radiation-containing regimens are efficient in
achieving better engraftments and widely used within
the UD-BMT settings for patients with SAA, although
these regimens are associated with significant early and
late toxicities, including secondary malignancies [22].
Recent study by Deeg et al. [20] to define the optimal










































Figure 2. Cumulative incidence of $ grade II aGVHD (A) and cGVHD (B) in patients with aplastic anemia who received UCBT.
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Figure 3. Probability of survival after conditioning regimens in patients with aplastic anemia, who received unrelated cord blood transplantation.
TBI: total body irradiation, CY: cyclophosphamide, MEL: melphalan, FLU: fludarabine, ATG: antithymocyte globulin.ATG for use with UD-BMT in patients with SAA
showed that 2 Gy was sufficient to allow engraftment
without increasing toxicities. This finding was also
supported by a Japanese study on UD-BMT in pa-
tients with SAA, which reported that in a small group
given a conditioning regimen of low-dose TBI (2-5
Gy), CY (200 mg/kg), and ATG, there was a 90%
survival rate [7].
Fludarabine is currently widely used for nonmye-
loablative transplants for a variety of diseases including
SAA [23-26]. In the recent study onUD-SCT from the
Severe Aplastic Anemia Working Party of the EBMT
(SAAWP-EBMT), they designed a non-TBI regimen
that used FLU (120 mg/m2), CY (1200 mg/m2), and
ATG [27]. In this study, a total of 38 both pediatric
and adults patients with SAA were included (36
BMT and 2 PBSCT patients) and the 2-year survival
rate was 73%, with a low incidence of aGVHD and
cGVHD. Therefore, this result suggests that a FLU
containing regimen might be effective for use with
UD-HSCT in SAA. The authors suggested that the
conditioning regimen might need to be modified for
adults through the addition of a low dose of TBI, as
there was a significantly lower engraftment rate seen
in the adult patients (82% overall, 68% in adults).
Overall, these findings in previous reports and in this
study suggest that the conditioning regimen that in-
cluded the low-dose TBI and FLU resulted in favor-
able outcomes. In present study, the 7 patients given
ATGwere poor. Only 1 of them achieved engraftment
and is alive. However, the number of patients given
ATG was too small to reach any definitive conclusions
and the benefit of ATG in UCBT for SAA should be
evaluated in a large prospective study.
The GVHD prophylaxis using a single agent (CSA
or tacrolimus) exhibited a better engraftment rate and
a marginally better survival rate compared to that seen
when 2 or more immunosuppressive agents were used.
In the latter group, steroid, MTX, or mycophenolate
mofetil (MMF) were given in addition to CSA or ta-
crolimus. Because of the limited number of patients
and the highly heterogeneous regimen of the GVHD
prophylaxis in this study, it is difficult to define the op-
timal GVHD prophylaxis based on the current results.However, the low incidence and severity of GVHD
that we noted in our study suggests that a single agent,
regardless of whether it is tacrolimus or CSA, may be
effective enough to prevent GVHD inUCBT for SAA.
One of the most important factors that determine
the success of UCBT is the cell dose in the CB
[11,28-30]. In the present study, a minimum of 2 
107/kg MNCs were infused in all patients. In this con-
dition, the dose of MNCs, CFU-GM, and CD34 had
no impact on engraftment and survival.One of the ben-
efits of UCBT is that it can overcome theHLA barrier.
Despite the HLA disparity in the majority of the pa-
tients, the incidence of GVHD was quite low in this
study. There was a tendency for better HLA matching
to result in a better outcome, although this was not sta-
tistically significant. Selection of the CB units with
higher cell dose and betterHLAmatchmay be essential
to improve the outcome of UCBT for SAA.
In our study there were also 8 patients who were
older than 50 years of age, which is generally consid-
ered to be over than the cutoff age for transplantation.
Because of the poor outcome of UCBT in older pa-
tients (OS 5 20% in group with age .40 years old),
UCBT cannot be recommended for older patients at
present, and repeated IST should be considered in
these patients [31,32].
In summary, this first multicentral study focused
on the UCBT for SAA suggests that UCBT can be
an alternative treatment for SAA patients who failed
to IST and have no suitable bone marrow donor.
The results may be improved by using the optimal
conditioning regimen such as low-dose TBI, FLU,
and CY and by donor selection of better HLA match
and higher cell dose.
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